{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:50:21Z","timestamp":1793724621977,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cca.2020.12.029","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:18:08Z","timestamp":1609424288000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Endometrial cancer: A systematic review of HE4, REM and REM-B"],"prefix":"10.1016","volume":"515","author":[{"given":"Manon","family":"Degez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Caillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chauvir\u00e9-Drouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5636-2041","authenticated-orcid":false,"given":"Maxime","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Thubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-0288","authenticated-orcid":false,"given":"Vincent","family":"Dochez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2020.12.029_b0005","unstructured":"Institut national de veille sanitaire. Projections de l\u2019incidence et de la mortalit\u00e9\u0301 par cancer en France en 2010, n.d. http:\/\/www.invs.sante.fr\/ (accessed May 1, 2019)."},{"key":"10.1016\/j.cca.2020.12.029_b0010","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International Patterns and Trends in Endometrial Cancer Incidence, 1978\u20132013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.cca.2020.12.029_b0015","unstructured":"Institut national du cancer Cancer de l\u2019endom\u00e8tre\u00a0: synth\u00e8se des recommandations., n.d. https:\/\/www.e-cancer.fr (accessed May 19, 2020)."},{"issue":"3","key":"10.1016\/j.cca.2020.12.029_b0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/beog.2000.0180","article-title":"Epidemiology of endometrial cancer","volume":"15","author":"Purdie","year":"2001","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.cca.2020.12.029_b0025","doi-asserted-by":"crossref","first-page":"F57","DOI":"10.1016\/S0368-2315(08)75574-1","article-title":"Endometrial cancer","volume":"37","author":"Collinet","year":"2008","journal-title":"J. Gynecol. Obstet. Biol. Reprod. (Paris)"},{"key":"10.1016\/j.cca.2020.12.029_b0030","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.bulcan.2017.10.006","article-title":"European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer","volume":"104","author":"Ballester","year":"2017","journal-title":"Bull. Cancer (Paris)"},{"issue":"5","key":"10.1016\/j.cca.2020.12.029_b0035","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2015.35","article-title":"Just how accurate are the major risk stratification systems for early-stage endometrial cancer?","volume":"112","author":"Bendifallah","year":"2015","journal-title":"Br. J. Cancer."},{"issue":"4","key":"10.1016\/j.cca.2020.12.029_b0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13277-012-0583-0","article-title":"The role of novel biomarker HE4 in endometrial cancer: a case control prospective study","volume":"34","author":"Angioli","year":"2013","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2020.12.029_b0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.cca.2020.12.029_b0055","unstructured":"Institut national du cancer .Conduites \u00e0 tenir initiales devant des patientes atteintes d\u2019un cancer \u00e9pith\u00e9lial de l\u2019ovaire .Synth\u00e8se, novembre 2018., n.d. https:\/\/www.e-cancer.fr (accessed June 12, 2019)."},{"issue":"2","key":"10.1016\/j.cca.2020.12.029_b0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A critical review on HE4 performance in endometrial cancer: where are we now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14737140.2017.1266263","article-title":"Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4","volume":"17","author":"Capriglione","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"12","key":"10.1016\/j.cca.2020.12.029_b0070","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14737159.2016.1251317","article-title":"Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies","volume":"16","author":"Qu","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"11","key":"10.1016\/j.cca.2020.12.029_b0075","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/jcm8111784","article-title":"Efficacy of HE4, CA125, risk of malignancy index and risk of ovarian malignancy index to detect ovarian cancer in women with presumed benign ovarian tumours: a prospective, multicentre trial","volume":"8","author":"Dochez","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2020.12.029_b0080","doi-asserted-by":"crossref","unstructured":"S. E, F. M, M. J, F. C, Obesity and Endometrial Cancer, Recent Results Cancer Res. 208:107\u2013136 (2016). https:\/\/doi.org\/10.1007\/978-3-319-42542-9_7.","DOI":"10.1007\/978-3-319-42542-9_7"},{"issue":"20","key":"10.1016\/j.cca.2020.12.029_b0085","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-13-1376","article-title":"REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy","volume":"19","author":"Angioli","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cca.2020.12.029_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-017-0945-y","article-title":"Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset","volume":"34","author":"Plotti","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cca.2020.12.029_b0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejogrb.2018.03.044","article-title":"Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey","volume":"225","author":"Plotti","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0100","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.4238\/2015.March.27.2","article-title":"Increased human epididymis protein 4 in benign gynecological diseases complicated with chronic renal insufficiency patients","volume":"14","author":"Lv","year":"2015","journal-title":"Genet. Mol. Res. GMR."},{"issue":"2","key":"10.1016\/j.cca.2020.12.029_b0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/01443615.2016.1174199","article-title":"The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions","volume":"37","author":"Y\u0131lmaz","year":"2017","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.cca.2020.12.029_b0115","first-page":"1239","article-title":"Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes","volume":"8","author":"Liu","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cca.2020.12.029_b0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2018.11.011","article-title":"Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: a meta-analysis","volume":"488","author":"Li","year":"2019","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2020.12.029_b0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.5603\/GP.2016.0088","article-title":"The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies","volume":"87","author":"Abdalla","year":"2016","journal-title":"Ginekol. Pol."},{"key":"10.1016\/j.cca.2020.12.029_b0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cca.2016.06.010","article-title":"Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China","volume":"459","author":"Li","year":"2016","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2020.12.029_b0135","first-page":"XC01","article-title":"Diagnostic performance of serum human epididymis protein 4 in endometrial Carcinoma: a pilot study","volume":"11","author":"Dewan","year":"2017","journal-title":"J. Clin. Diagn. Res. JCDR."},{"key":"10.1016\/j.cca.2020.12.029_b0140","first-page":"1974","article-title":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis","volume":"20","author":"Chen","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.cca.2020.12.029_b0145","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1089\/gtmb.2019.0046","article-title":"Serum human epididymis protein 4 combined with carbohydrate antigen 125 for endometrial carcinoma diagnosis: a meta-analysis and systematic review","volume":"23","author":"Huang","year":"2019","journal-title":"Genet. Test. Mol. Biomark."},{"issue":"5","key":"10.1016\/j.cca.2020.12.029_b0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/uog.1704","article-title":"How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding","volume":"24","author":"Smith-Bindman","year":"2004","journal-title":"Ultrasound Obstet."},{"issue":"4","key":"10.1016\/j.cca.2020.12.029_b0155","doi-asserted-by":"crossref","first-page":"549.e1","DOI":"10.1016\/j.ajog.2020.03.032","article-title":"Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms","volume":"223","author":"Clarke","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.cca.2020.12.029_b0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.radonc.2015.11.013","article-title":"ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group, ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up","volume":"117","author":"Colombo","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.cca.2020.12.029_b0165","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2147\/OTT.S136750","article-title":"Clinical importance of serum HE4 and MMP2 levels in endometrial cancer patients","volume":"10","author":"Cymbaluk-P\u0142oska","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cca.2020.12.029_b0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.17772\/gp\/62356","article-title":"The role of HE4 in differentiating benign and malignant endometrial pathology","volume":"87","author":"G\u0105siorowska","year":"2016","journal-title":"Ginekol. Pol."},{"issue":"11","key":"10.1016\/j.cca.2020.12.029_b0175","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/aogs.12235","article-title":"HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET)","volume":"92","author":"Antonsen","year":"2013","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"6","key":"10.1016\/j.cca.2020.12.029_b0180","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s13277-015-3049-3","article-title":"Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study","volume":"36","author":"Capriglione","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2020.12.029_b0185","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","article-title":"Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome","volume":"50","author":"Zanotti","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"issue":"9","key":"10.1016\/j.cca.2020.12.029_b0190","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","article-title":"Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients","volume":"104","author":"Bignotti","year":"2011","journal-title":"Br. J. Cancer."},{"issue":"2","key":"10.1016\/j.cca.2020.12.029_b0195","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318757103","article-title":"HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients","volume":"40","author":"Abbink","year":"2018","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0200","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ijgo.12010","article-title":"Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer","volume":"136","author":"Wang","year":"2017","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.cca.2020.12.029_b0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ygyno.2011.10.025","article-title":"Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer","volume":"124","author":"Kalogera","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2013.10.036","article-title":"Serum HE4 as a prognostic marker in endometrial cancer\u2013a population based study","volume":"132","author":"Brennan","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2020.12.029_b0215","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/IGC.0000000000001015","article-title":"Preoperative serum human epididymis protein 4 levels in early stage endometrial cancer: a prospective study","volume":"27","author":"Fanfani","year":"2017","journal-title":"Int. J. Gynecol. Cancer."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ygyno.2017.07.130","article-title":"Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer","volume":"147","author":"Knific","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2020.12.029_b0225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00428-017-2115-1","article-title":"Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer","volume":"470","author":"Stiekema","year":"2017","journal-title":"Virchows Arch. Int. J. Pathol."},{"issue":"2","key":"10.1016\/j.cca.2020.12.029_b0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","article-title":"HE4 is an independent prognostic marker in endometrial cancer patients","volume":"126","author":"Mutz-Dehbalaie","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.cca.2020.12.029_b0235","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00404-019-05276-9","article-title":"Risk factors for pelvic lymph node metastasis in endometrial cancer","volume":"300","author":"Li","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2015.11.020","article-title":"Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer","volume":"140","author":"Kemik","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2020.12.029_b0245","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00404-016-4181-z","article-title":"Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers","volume":"294","author":"Angioli","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.cca.2020.12.029_b0250","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.21873\/anticanres.11619","article-title":"Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management","volume":"37","author":"Presl","year":"2017","journal-title":"Anticancer Res."},{"issue":"142","key":"10.1016\/j.cca.2020.12.029_b0255","first-page":"e1","article-title":"Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma","volume":"209","author":"Saarelainen","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.cca.2020.12.029_b0260","doi-asserted-by":"crossref","first-page":"10528","DOI":"10.1038\/s41598-017-11104-4","article-title":"RERT: a novel regression tree approach to predict extrauterine disease in endometrial carcinoma patients","volume":"7","author":"Vezzoli","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.cca.2020.12.029_b0265","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","article-title":"Cancer care Ontario program in evidence-based care gynecology cancer disease site group, follow-up after primary therapy for endometrial cancer: a systematic review","volume":"101","author":"Fung-Kee-Fung","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2020.12.029_b0270","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: society of gynecologic oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.cca.2020.12.029_b0275","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1007\/s13277-015-4324-z","article-title":"The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program","volume":"37","author":"Angioli","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2020.12.029_b0280","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12885-015-1028-0","article-title":"Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance","volume":"15","author":"Brennan","year":"2015","journal-title":"BMC Can."},{"key":"10.1016\/j.cca.2020.12.029_b0285","first-page":"4491","article-title":"Prognostic values of HE4 expression in patients with cancer: a meta-analysis","volume":"10","author":"Dai","year":"2018","journal-title":"Can. Manage. Res."},{"issue":"4","key":"10.1016\/j.cca.2020.12.029_b0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/1533034616666644","article-title":"Clinical significance of serum HE4, CA125, CA724, and CA19-9 in patients with endometrial cancer","volume":"16","author":"Bian","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.cca.2020.12.029_b0295","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/14737159.2016.1258302","article-title":"Discovery of biomarkers for endometrial cancer: current status and prospects","volume":"16","author":"Ri\u017ener","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.cca.2020.12.029_b0300","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819901117","article-title":"A new risk index combining d-dimer, fibrinogen, HE4, and CA199 differentiates suspecting endometrial cancer from patients with abnormal vaginal bleeding or discharge","volume":"19","author":"Ge","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0305","doi-asserted-by":"crossref","first-page":"e22223","DOI":"10.1002\/jcla.22223","article-title":"The clinical significance of DJ-1 and HE4 in patients with endometrial cancer","volume":"32","author":"Benati","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.cca.2020.12.029_b0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.23736\/S0026-4784.18.04328-9","article-title":"The role of human epididymis protein 4 as a biomarker in gynecologic malignancies","volume":"71","author":"Plotti","year":"2019","journal-title":"Minerva Ginecol."},{"key":"10.1016\/j.cca.2020.12.029_b0315","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2018.03.040","article-title":"Human epididymis protein 4 in endometrial cancer: A meta-analysis","volume":"482","author":"Li","year":"2018","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2020.12.029_b0320","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12669\/pjms.334.12755","article-title":"Value of HE4 Combined with Cancer Antigen 125 in the Diagnosis of Endometrial Cancer","volume":"33","author":"Dong","year":"2017","journal-title":"Pak. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.cca.2020.12.029_b0325","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1477-7819-12-169","article-title":"Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis","volume":"12","author":"Bie","year":"2014","journal-title":"World J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2020.12.029_b0330","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s13277-013-0814-z","article-title":"The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients","volume":"34","author":"Omer","year":"2013","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cca.2020.12.029_b0335","first-page":"133","article-title":"Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer","volume":"15","author":"Abdalla","year":"2016","journal-title":"Przeglad Menopauzalny."},{"issue":"3","key":"10.1016\/j.cca.2020.12.029_b0340","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7314\/APJCP.2016.17.3.1489","article-title":"Association of serum HE4 with primary tumor diameter and depth of myometrial invasion in endometrial cancer patients at Rajavithi hospital","volume":"17","author":"Prueksaritanond","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"10","key":"10.1016\/j.cca.2020.12.029_b0345","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jog.12764","article-title":"Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging","volume":"41","author":"Minar","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.cca.2020.12.029_b0350","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/IGC.0b013e3182229ad8","article-title":"Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus","volume":"21","author":"Moore","year":"2011","journal-title":"Int. J. Gynecol. Can."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120305970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120305970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:56:39Z","timestamp":1757861799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898120305970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":70,"alternative-id":["S0009898120305970"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.029","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endometrial cancer: A systematic review of HE4, REM and REM-B","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}